Literature DB >> 21960346

Imbalanced expression of mitogen-activated protein kinase phosphatase-1 and phosphorylated extracellular signal-regulated kinases in lung squamous cell carcinoma.

Kai Wang1, Min Zhang, Ying-ying Qian, Zhe-yuan Ding, Jun-hui Lv, Hua-hao Shen.   

Abstract

OBJECTIVE: Mitogen-activated protein kinases (MAPKs) are correlated with a more malignant phenotype in many cancers. This study was designed to evaluate the predictive value of the expression of MAPK phosphatase-1 (MKP-1) and phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK(1/2)), as the key regulatory mechanism of the MAPKs, in lung squamous cell carcinoma (SCC).
METHODS: We assessed the expressions of MKP-1 and p-ERK(1/2) in twenty subjects at different differentiation degree of SCC and five normal lungs by immunohistochemistry and real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis.
RESULTS: Immunohistochemistry and real-time RT-PCR assay showed that the expression of MKP-1 was gradually decreased as tissue type went from normal lung tissues to increasingly undifferentiated carcinoma, and it was negatively correlated with tumor differentiation (P<0.01). However, the expression of p-ERK(1/2) or ERK(1/2) was gradually increased as tissue type went from normal lung tissues to increasingly undifferentiated carcinoma, and it was positively correlated with tumor differentiation (P<0.01).
CONCLUSIONS: Our data indicates the relevance of MKP-1 and p-ERK(1/2) in SCC as a potential positive and negative prognostic factor. The imbalanced expression of MKP-1 and p-ERK(1/2) may play a role in the development of SCC and these two molecules may be new targets for the therapy and prognosis of SCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21960346      PMCID: PMC3190098          DOI: 10.1631/jzus.B1100165

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  32 in total

Review 1.  The MEK/ERK cascade: from signaling specificity to diverse functions.

Authors:  Yoav D Shaul; Rony Seger
Journal:  Biochim Biophys Acta       Date:  2006-10-19

Review 2.  The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling.

Authors:  Katherine L Dunn; Paula S Espino; Bojan Drobic; Shihua He; James R Davie
Journal:  Biochem Cell Biol       Date:  2005-02       Impact factor: 3.626

3.  Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma.

Authors:  Eiji Tsujita; Akinobu Taketomi; Tomonobu Gion; Yousuke Kuroda; Kazuya Endo; Akihiro Watanabe; Hideaki Nakashima; Shin-ichi Aishima; Shunji Kohnoe; Yoshihiko Maehara
Journal:  Oncology       Date:  2005-11-16       Impact factor: 2.935

Review 4.  MAPK signal specificity: the right place at the right time.

Authors:  Leon O Murphy; John Blenis
Journal:  Trends Biochem Sci       Date:  2006-04-17       Impact factor: 13.807

Review 5.  Diverse physiological functions for dual-specificity MAP kinase phosphatases.

Authors:  Robin J Dickinson; Stephen M Keyse
Journal:  J Cell Sci       Date:  2006-11-15       Impact factor: 5.285

Review 6.  The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting.

Authors:  Marie A Bogoyevitch
Journal:  Bioessays       Date:  2006-09       Impact factor: 4.345

7.  Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2.

Authors:  Loredana Moro; Arnaldo A Arbini; Ersilia Marra; Margherita Greco
Journal:  Int J Oncol       Date:  2007-01       Impact factor: 5.650

Review 8.  Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases.

Authors:  D M Owens; S M Keyse
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

9.  Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.

Authors:  Dan Huang; Yan Ding; Wang-Mei Luo; Stephanie Bender; Chao-Nan Qian; Eric Kort; Zhong-Fa Zhang; Kristin VandenBeldt; Nicholas S Duesbery; James H Resau; Bin Tean Teh
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

Review 10.  Inhibitors of c-Jun N-terminal kinases: JuNK no more?

Authors:  Marie A Bogoyevitch; Peter G Arthur
Journal:  Biochim Biophys Acta       Date:  2007-10-11
View more
  4 in total

1.  Cellular intrinsic factors involved in the resistance of squamous cell carcinoma to photodynamic therapy.

Authors:  Yolanda Gilaberte; Laura Milla; Nerea Salazar; Jesús Vera-Alvarez; Omar Kourani; Alejandra Damian; Viviana Rivarola; Maria José Roca; Jesús Espada; Salvador González; Angeles Juarranz
Journal:  J Invest Dermatol       Date:  2014-04-09       Impact factor: 8.551

2.  Expression profiling of cervical cancers in Indian women at different stages to identify gene signatures during progression of the disease.

Authors:  Asha Thomas; Umesh Mahantshetty; Sadhana Kannan; Kedar Deodhar; Shyam K Shrivastava; Chandan Kumar-Sinha; Rita Mulherkar
Journal:  Cancer Med       Date:  2013-10-31       Impact factor: 4.452

3.  DUSP1 is involved in the progression of small cell carcinoma of the prostate.

Authors:  Yajing Zhang; Yan Zhang; Meng Chen; Ci Liu; Cheng Xiang
Journal:  Saudi J Biol Sci       Date:  2017-10-18       Impact factor: 4.219

4.  Identification of the differentially expressed proteins in nasopharyngeal carcinoma by proteomics.

Authors:  Dongxiu Rong; Xiuxian Lin; Yanzhang Luo; Tin Seak Mok; Qing Wang; Haiyan Wang; Tao Zhang
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.